<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00427635</url>
  </required_header>
  <id_info>
    <org_study_id>D9614C00004</org_study_id>
    <nct_id>NCT00427635</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Esomeprazole Once Daily for the Treatment of GERD in Neonatal Patients</brief_title>
  <official_title>A Randomized, Double-blind, Placebo Controlled, Study to Evaluate the Efficacy and Safety of Esomeprazole Once Daily for the Treatment of Gastroesophageal Reflux Disease (GERD) in Neonatal Patients, Including Premature and up to 1 Month Corrected Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the difference between esomeprazole and placebo in the
      treatment of signs and symptoms as observed by 8-hour video and cardiorespiratory monitoring
      in neonatal patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Normalized Number of GERD Events Observed From Video and Cardiorespiratory Monitoring</measure>
    <time_frame>Baseline and end of treatment (10-14 days)</time_frame>
    <description>The number of events are normalized prior to summary to correspond to a complete 8-hour monitoring period. Only patients with data at both baseline and final assessment are included.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Normalized Number of GERD Events During Video and Cardiorespiratory Monitoring Associated With Acid Reflux</measure>
    <time_frame>Baseline and end of treatment (10-14 days)</time_frame>
    <description>Event considered associated with reflux if start time of GERD sign/symptom is within 2 minutes of start time of acid reflux. The number of events are normalized prior to summary to correspond to a complete 8-hour monitoring period. Only patients with data at both baseline and final assessment are included.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Number of Reflux Episodes (Acid or Non-acid)</measure>
    <time_frame>Baseline and end of treatment (10-14 days)</time_frame>
    <description>Number of reflux episodes based on 24-hour impedance monitoring data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Number of Acidic Reflux Episodes</measure>
    <time_frame>Baseline and end of treatment (10-14 days)</time_frame>
    <description>Number of reflux episodes (pH&lt;4.0) based on 24-hour impedance monitoring data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Number of Weakly Acidic Reflux Episodes</measure>
    <time_frame>Baseline and end of treatment (10-14 days)</time_frame>
    <description>Number of reflux episodes (pH 4.0-6.9) based on 24-hour impedance monitoring data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Number of Non Acidic Reflux Episodes</measure>
    <time_frame>Baseline and end of treatment (10-14 days)</time_frame>
    <description>Number of reflux episodes (pH&gt;=7.0) based on 24-hour impedance monitoring data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Number of Liquid Acidic Reflux Episodes</measure>
    <time_frame>Baseline and end of treatment (10-14 days)</time_frame>
    <description>Number of reflux episodes based on 24-hour impedance monitoring data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Number of Mixed Gas/Liquid Acidic Reflux Episodes</measure>
    <time_frame>Baseline and end of treatment (10-14 days)</time_frame>
    <description>Number of reflux episodes based on 24-hour impedance monitoring data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Bolus Clearance Time</measure>
    <time_frame>Baseline and end of treatment (10-14 days)</time_frame>
    <description>Based on 24-hour impedance monitoring data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Acid Clearance Time</measure>
    <time_frame>Baseline and end of treatment (10-14 days)</time_frame>
    <description>Based on 24-hour impedance monitoring data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percentage Time With pH&lt;4.0</measure>
    <time_frame>Baseline and end of treatment (10-14 days)</time_frame>
    <description>Percentage time with pH&lt;4 during 24-hour pH monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percentage Time With pH Within 4.0-6.9</measure>
    <time_frame>Baseline and end of treatment (10-14 days)</time_frame>
    <description>Percentage time with pH 4.0-6.9 during 24-hour pH monitoring</description>
  </secondary_outcome>
  <enrollment type="Actual">32</enrollment>
  <condition>GERD</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Full-term or gestational age &gt;/= 28 to 44 weeks

          -  In-patient in Neonatal Intensive Care Unit, special care nursery, or equivalent

          -  Patient must be on a stable mode of feeding or with minimal variations for at least 2
             days prior to randomization

        Exclusion Criteria:

          -  Patients with a need for resectional or reconstructive surgery of the gastrointestinal
             tract

          -  Patients with any condition that may require surgery during the course of the study

          -  Patients with acute respiratory distress within 72 hours prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Month</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marta Illueca, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Per Lundborg, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathryn Collison, MPH, MT(ASCP)</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>North Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.astrazeneca.com/node/emailtriage.aspx</url>
    <description>AstraZeneca Clinical Trial Information</description>
  </link>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2007</study_first_submitted>
  <study_first_submitted_qc>January 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2007</study_first_posted>
  <results_first_submitted>April 19, 2010</results_first_submitted>
  <results_first_submitted_qc>April 19, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 19, 2010</results_first_posted>
  <last_update_submitted>December 2, 2010</last_update_submitted>
  <last_update_submitted_qc>December 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2010</last_update_posted>
  <keyword>neonates</keyword>
  <keyword>infants</keyword>
  <keyword>GERD</keyword>
  <keyword>reflux</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants either full term or those with a gestational age or post-conceptual age Â³28 to 44 weeks, and who were inpatients suspected of having the following clinical findings: any 2 (either individually or in any combination) of (1) apnea +/- bradycardia +/- oxygen desaturations, (2) vomiting/gagging, (3) irritability/pain at least every second</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Esomeprazole</title>
          <description>Esomeprazole 0.5 mg/kg/ day once daily 30 minutes prior to a morning feeding during 15 days by oral gavage (using a nasogastric or orogastric tube) or by nippling.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo once daily 30 minutes prior to a morning feeding during 15 days by oral gavage (using a nasogastric or orogastric tube) or by nippling.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26">Randomised</participants>
                <participants group_id="P2" count="26">Randomised</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25">ITT population. One voluntary discontinuation by parent/guardian</participants>
                <participants group_id="P2" count="26">ITT population</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Study Completion to Safety Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25">One participant lost to follow-up</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Esomeprazole</title>
          <description>Esomeprazole 0.5 mg/kg/ day once daily 30 minutes prior to a morning feeding during 15 days by oral gavage (using a nasogastric or orogastric tube) or by nippling.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo once daily 30 minutes prior to a morning feeding during 15 days by oral gavage (using a nasogastric or orogastric tube) or by nippling.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.5" spread="30.3"/>
                    <measurement group_id="B2" value="46.5" spread="31.2"/>
                    <measurement group_id="B3" value="46.5" spread="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Normalized Number of GERD Events Observed From Video and Cardiorespiratory Monitoring</title>
        <description>The number of events are normalized prior to summary to correspond to a complete 8-hour monitoring period. Only patients with data at both baseline and final assessment are included.</description>
        <time_frame>Baseline and end of treatment (10-14 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole</title>
            <description>Esomeprazole 0.5 mg/kg/ day once daily 30 minutes prior to a morning feeding during 15 days by oral gavage (using a nasogastric or orogastric tube) or by nippling.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily 30 minutes prior to a morning feeding during 15 days by oral gavage (using a nasogastric or orogastric tube) or by nippling.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Normalized Number of GERD Events Observed From Video and Cardiorespiratory Monitoring</title>
          <description>The number of events are normalized prior to summary to correspond to a complete 8-hour monitoring period. Only patients with data at both baseline and final assessment are included.</description>
          <units>Mean Number of Events</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.01" spread="77.70"/>
                    <measurement group_id="O2" value="-24.79" spread="44.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Normalized Number of GERD Events During Video and Cardiorespiratory Monitoring Associated With Acid Reflux</title>
        <description>Event considered associated with reflux if start time of GERD sign/symptom is within 2 minutes of start time of acid reflux. The number of events are normalized prior to summary to correspond to a complete 8-hour monitoring period. Only patients with data at both baseline and final assessment are included.</description>
        <time_frame>Baseline and end of treatment (10-14 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole</title>
            <description>Esomeprazole 0.5 mg/kg/ day once daily 30 minutes prior to a morning feeding during 15 days by oral gavage (using a nasogastric or orogastric tube) or by nippling.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily 30 minutes prior to a morning feeding during 15 days by oral gavage (using a nasogastric or orogastric tube) or by nippling.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Normalized Number of GERD Events During Video and Cardiorespiratory Monitoring Associated With Acid Reflux</title>
          <description>Event considered associated with reflux if start time of GERD sign/symptom is within 2 minutes of start time of acid reflux. The number of events are normalized prior to summary to correspond to a complete 8-hour monitoring period. Only patients with data at both baseline and final assessment are included.</description>
          <units>Mean Number of Events</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.79" spread="40.37"/>
                    <measurement group_id="O2" value="-13.49" spread="32.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Number of Reflux Episodes (Acid or Non-acid)</title>
        <description>Number of reflux episodes based on 24-hour impedance monitoring data</description>
        <time_frame>Baseline and end of treatment (10-14 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole</title>
            <description>Esomeprazole 0.5 mg/kg/ day once daily 30 minutes prior to a morning feeding during 15 days by oral gavage (using a nasogastric or orogastric tube) or by nippling.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily 30 minutes prior to a morning feeding during 15 days by oral gavage (using a nasogastric or orogastric tube) or by nippling.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Number of Reflux Episodes (Acid or Non-acid)</title>
          <description>Number of reflux episodes based on 24-hour impedance monitoring data</description>
          <units>Mean Number of Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.55" spread="49.58"/>
                    <measurement group_id="O2" value="6.27" spread="28.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Number of Acidic Reflux Episodes</title>
        <description>Number of reflux episodes (pH&lt;4.0) based on 24-hour impedance monitoring data</description>
        <time_frame>Baseline and end of treatment (10-14 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole</title>
            <description>Esomeprazole 0.5 mg/kg/ day once daily 30 minutes prior to a morning feeding during 15 days by oral gavage (using a nasogastric or orogastric tube) or by nippling.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily 30 minutes prior to a morning feeding during 15 days by oral gavage (using a nasogastric or orogastric tube) or by nippling.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Number of Acidic Reflux Episodes</title>
          <description>Number of reflux episodes (pH&lt;4.0) based on 24-hour impedance monitoring data</description>
          <units>Mean Number of Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.75" spread="32.38"/>
                    <measurement group_id="O2" value="2.36" spread="18.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Number of Weakly Acidic Reflux Episodes</title>
        <description>Number of reflux episodes (pH 4.0-6.9) based on 24-hour impedance monitoring data</description>
        <time_frame>Baseline and end of treatment (10-14 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole</title>
            <description>Esomeprazole 0.5 mg/kg/ day once daily 30 minutes prior to a morning feeding during 15 days by oral gavage (using a nasogastric or orogastric tube) or by nippling.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily 30 minutes prior to a morning feeding during 15 days by oral gavage (using a nasogastric or orogastric tube) or by nippling.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Number of Weakly Acidic Reflux Episodes</title>
          <description>Number of reflux episodes (pH 4.0-6.9) based on 24-hour impedance monitoring data</description>
          <units>Mean Number of Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.60" spread="45.17"/>
                    <measurement group_id="O2" value="3.59" spread="21.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Number of Non Acidic Reflux Episodes</title>
        <description>Number of reflux episodes (pH&gt;=7.0) based on 24-hour impedance monitoring data</description>
        <time_frame>Baseline and end of treatment (10-14 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole</title>
            <description>Esomeprazole 0.5 mg/kg/ day once daily 30 minutes prior to a morning feeding during 15 days by oral gavage (using a nasogastric or orogastric tube) or by nippling.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily 30 minutes prior to a morning feeding during 15 days by oral gavage (using a nasogastric or orogastric tube) or by nippling.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Number of Non Acidic Reflux Episodes</title>
          <description>Number of reflux episodes (pH&gt;=7.0) based on 24-hour impedance monitoring data</description>
          <units>Mean Number of Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="1.14"/>
                    <measurement group_id="O2" value="0.32" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Number of Liquid Acidic Reflux Episodes</title>
        <description>Number of reflux episodes based on 24-hour impedance monitoring data</description>
        <time_frame>Baseline and end of treatment (10-14 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole</title>
            <description>Esomeprazole 0.5 mg/kg/ day once daily 30 minutes prior to a morning feeding during 15 days by oral gavage (using a nasogastric or orogastric tube) or by nippling.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily 30 minutes prior to a morning feeding during 15 days by oral gavage (using a nasogastric or orogastric tube) or by nippling.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Number of Liquid Acidic Reflux Episodes</title>
          <description>Number of reflux episodes based on 24-hour impedance monitoring data</description>
          <units>Mean Number of Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.00" spread="52.03"/>
                    <measurement group_id="O2" value="3.05" spread="31.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Number of Mixed Gas/Liquid Acidic Reflux Episodes</title>
        <description>Number of reflux episodes based on 24-hour impedance monitoring data</description>
        <time_frame>Baseline and end of treatment (10-14 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole</title>
            <description>Esomeprazole 0.5 mg/kg/ day once daily 30 minutes prior to a morning feeding during 15 days by oral gavage (using a nasogastric or orogastric tube) or by nippling.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily 30 minutes prior to a morning feeding during 15 days by oral gavage (using a nasogastric or orogastric tube) or by nippling.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Number of Mixed Gas/Liquid Acidic Reflux Episodes</title>
          <description>Number of reflux episodes based on 24-hour impedance monitoring data</description>
          <units>Mean Number of Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.45" spread="17.44"/>
                    <measurement group_id="O2" value="3.27" spread="13.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Bolus Clearance Time</title>
        <description>Based on 24-hour impedance monitoring data</description>
        <time_frame>Baseline and end of treatment (10-14 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole</title>
            <description>Esomeprazole 0.5 mg/kg/ day once daily 30 minutes prior to a morning feeding during 15 days by oral gavage (using a nasogastric or orogastric tube) or by nippling.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily 30 minutes prior to a morning feeding during 15 days by oral gavage (using a nasogastric or orogastric tube) or by nippling.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Bolus Clearance Time</title>
          <description>Based on 24-hour impedance monitoring data</description>
          <units>Seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="24.56"/>
                    <measurement group_id="O2" value="-4.05" spread="25.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Acid Clearance Time</title>
        <description>Based on 24-hour impedance monitoring data</description>
        <time_frame>Baseline and end of treatment (10-14 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole</title>
            <description>Esomeprazole 0.5 mg/kg/ day once daily 30 minutes prior to a morning feeding during 15 days by oral gavage (using a nasogastric or orogastric tube) or by nippling.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily 30 minutes prior to a morning feeding during 15 days by oral gavage (using a nasogastric or orogastric tube) or by nippling.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Acid Clearance Time</title>
          <description>Based on 24-hour impedance monitoring data</description>
          <units>Seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.93" spread="64.32"/>
                    <measurement group_id="O2" value="-6.36" spread="45.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percentage Time With pH&lt;4.0</title>
        <description>Percentage time with pH&lt;4 during 24-hour pH monitoring</description>
        <time_frame>Baseline and end of treatment (10-14 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole</title>
            <description>Esomeprazole 0.5 mg/kg/ day once daily 30 minutes prior to a morning feeding during 15 days by oral gavage (using a nasogastric or orogastric tube) or by nippling.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily 30 minutes prior to a morning feeding during 15 days by oral gavage (using a nasogastric or orogastric tube) or by nippling.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percentage Time With pH&lt;4.0</title>
          <description>Percentage time with pH&lt;4 during 24-hour pH monitoring</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.73" spread="12.63"/>
                    <measurement group_id="O2" value="2.24" spread="12.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percentage Time With pH Within 4.0-6.9</title>
        <description>Percentage time with pH 4.0-6.9 during 24-hour pH monitoring</description>
        <time_frame>Baseline and end of treatment (10-14 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esomeprazole</title>
            <description>Esomeprazole 0.5 mg/kg/ day once daily 30 minutes prior to a morning feeding during 15 days by oral gavage (using a nasogastric or orogastric tube) or by nippling.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily 30 minutes prior to a morning feeding during 15 days by oral gavage (using a nasogastric or orogastric tube) or by nippling.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percentage Time With pH Within 4.0-6.9</title>
          <description>Percentage time with pH 4.0-6.9 during 24-hour pH monitoring</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.84" spread="12.64"/>
                    <measurement group_id="O2" value="-2.60" spread="12.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Esomeprazole</title>
          <description>Esomeprazole 0.5 mg/kg/ day once daily 30 minutes prior to a morning feeding during 15 days by oral gavage (using a nasogastric or orogastric tube) or by nippling.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo once daily 30 minutes prior to a morning feeding during 15 days by oral gavage (using a nasogastric or orogastric tube) or by nippling.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia Neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cyanosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Inappropriate Device Signal Detection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Infantile Apnoeic Attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia Neonatal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cyanosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness Neurosensory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Retinopathy Of Prematurity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Neonatal Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection Neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oxygen Saturation Decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

